Westmead Hospital

Running trials

• Not yet recruiting

  Baerveldt Versus Paul Study

  NCT07733453· Phase 4· Source

• Recruiting

  Evaluation of XYA02 in Patients With Advanced Solid Tumors

  NCT07670312· Phase 1/2· Source

• Recruiting

  Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

  NCT07197580· Phase 3· Source

• Recruiting

  A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

  NCT07255404· Phase 2· Source

• Recruiting

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Source

• Recruiting

  Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  NCT06824168· Phase 2· Source

• Active, not recruiting

  A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

  NCT06649695· Phase 2· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Source

• Recruiting

  Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

  NCT06510699· Phase 2· Source

• Recruiting

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Phase 3· Source

• Active, not recruiting

  Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

  NCT06727565· Phase 2· Source

• Active, not recruiting

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· Phase 3· Source

• Recruiting

  SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)

  NCT06278857· Phase 2· Source

• Recruiting

  The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

  NCT06520345· Phase 3· Source

• Active, not recruiting

  IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

  NCT05987332· Phase 2/3· Source

• Recruiting

  The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

  NCT05804331· Source

• Active, not recruiting

  The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

  NCT05374291· Phase 3· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Source

• Recruiting

  Real World Assessment of People Living With Chronic Hepatitis B in Australia

  NCT04914611· Source

• Active, not recruiting

  Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

  NCT05796089· Phase 2· Source

• Recruiting

  Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease

  NCT05136222· Source

• Active, not recruiting

  Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

  NCT04949113· Phase 3· Source

• Recruiting

  Personalised Immunotherapy Platform

  NCT06536257· Source

• Recruiting

  Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment

  NCT04434807· Source

• Active, not recruiting

  Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

  NCT04291885· Phase 2· Source

• Recruiting

  TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

  NCT04294927· Source

• Recruiting

  Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

  NCT03860883· Source

• Enrolling by invitation

  A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

  NCT03683186· Phase 3· Source

• Recruiting

  Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

  NCT03340129· Phase 2· Source

• Recruiting

  Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

  NCT03947385· Phase 1/2· Source

• Active, not recruiting

  First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

  NCT03625037· Phase 1/2· Source

• Active, not recruiting

  Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

  NCT02858921· Phase 2· Source

• Recruiting

  International Registry for Men With Advanced Prostate Cancer (IRONMAN)

  NCT03151629· Source

• Active, not recruiting

  A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

  NCT03165734· Phase 3· Source

• Recruiting

  Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

  NCT02823821· Phase 4· Source

• Active, not recruiting

  Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

  NCT01924819· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Melanoma3 recruiting
• Ovarian cancer3 recruiting
• Colorectal cancer2 recruiting
• Gastric and esophageal cancer2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Acute myeloid leukemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Endometrial cancer1 recruiting
• Glaucoma1 recruiting
• Hepatitis B1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroendocrine tumours1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Terminated

  A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

  NCT05605522· Phase 1· Source

• Recruiting

  Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

  NCT05518578· Phase 2· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

  NCT05358717· Phase 2· Source

• Completed

  An Implementation Trial to Improve Access to Pulmonary Rehabilitation in People With COPD

  NCT04217330· Source

• Completed

  Preventing Adverse Cardiac Events in COPD

  NCT03917914· Phase 3· Source

• Completed

  A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

  NCT03497767· Phase 2· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· Source

• Completed

  Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma

  NCT02166788· Phase 3· Source